Cargando…
ALK抑制剂在治疗NSCLC脑转移中的疗效及安全性研究进展
Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been reported that 5%-6% of patients with brain metastases...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273149/ https://www.ncbi.nlm.nih.gov/pubmed/37316450 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.10 |